Where does Emboline, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Emboline, Inc. ranks #13,963 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Emboline, Inc. hold?

Emboline, Inc. holds 21 US utility patents granted between 2015 and 2025, spanning 3 technology areas.

What is Emboline, Inc.'s Innovation Score?

Emboline, Inc. has an Innovation Score of 29.9 out of 100 (32nd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Emboline, Inc.'s patent grant rate increasing or decreasing?

Emboline, Inc.'s recent grant velocity is +43% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Emboline, Inc.'s patents?

Emboline, Inc.'s patents average 17.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Emboline, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Emboline, Inc.

Q: What technology areas does Emboline, Inc. focus on?

Emboline, Inc.'s top technology area is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs) with 21 patents, ranking #308 of 3,082 assignees active in that subclass. Grants appear in 3 CPC subclasses total.

USPTO PatentsView assignee record - 21 granted patents across 3 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Emboline ranks #13,963 of 49,997 tracked US assignees by granted-patent volume, with 21 patents across 3 technology areas.

#13,963
of 49,997 US assignees by volume: 32nd percentile
by Innovation Score (29.9/100): 17.7
avg claims per patent: +43%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R13963 · US Corporation #13,963 · 21 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-UP · BOOK-FULL

GRANTS-SMALL 21 grants
MID-PACK #13,963/49,997
PHOTO-FINISH Ecole Normale…
CPC-NARROW A61F · 3 areas
INNOV-THIN 29.9/100
CLAIMS-RICH 17.7 claims/avg
TYPE-USCORP US Corporation
VEL-UP +43% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Ecole Normale Superieure De Cachan (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Emboline’s 29.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.7 pts (36%) Velocity 2.5 pts (8%) Breadth 6.1 pts (20%) Claim depth 10.6 pts (35%)

Qualcomm Incorporated · highest

85
Emboline · this assignee

30
3D Lighting… · lowest

7

What this shows Emboline's Innovation Score is 29.9/100 (32nd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Emboline?

Each dot is one of Emboline’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Emboline’s own 17.7 claims/patent is ABOVE the 15.2 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Emboline vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Emboline's grants concentrate

Emboline, Inc. is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device). Peak complete grant year is 2020 (4 grants) versus a trough of 1 in 2015. By volume, Emboline sits between Exela Pharma Sciences, LLC and Enable Injections, Inc..

Emboline's three-year grant acceleration

Emboline, Inc. shows 3 grants in 2022–2024 against only 8 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Exela Pharma Scie…

21
Ecole Normale Sup…

21
Imaging Services

21
Elsevier

21
Embry-riddle Aero…

21
Emerson Climate (…

21
Enpower

21
Enable Injections

21
Emboline ◀

21

What this shows Emboline holds 21 patents at rank #13,969, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Emboline

By rank, the assignees closest to #13,969 in granted patent volume.

Leaders in A61F (Filters Implantable Into Blood Vessels)

Other assignees with the most granted patents in Emboline's primary technology class.

Emboline's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

30 32nd percentile higher than 32% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Emboline, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	4.8%
2016	1	4.8%
2017	2	9.5%
2018	2	9.5%
2019	1	4.8%
2020	4	19.0%
2021	3	14.3%
2022	2	9.5%
2024	1	4.8%
2025partial year	4	19.0%

Which technologies does Emboline, Inc. patent most?

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 21

A47C - CHAIRS; SOFAS; Beds 7

A61B - DIAGNOSIS; SURGERY; Identification 3

Top 3 of 3 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Emboline, Inc.'s patent record in context - here's where to go next.

Emboline, Inc.'s lead technology class is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device), 100% of its portfolio - see every assignee active in that class. Explore A61F
Ranked #13,963 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Emboline, Inc. against Exela Pharma Sciences, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 29.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.